Mutual of America Capital Management LLC Acquires 124,165 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Mutual of America Capital Management LLC boosted its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 31.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 521,937 shares of the medical equipment provider's stock after buying an additional 124,165 shares during the quarter. Mutual of America Capital Management LLC owned 1.13% of BioLife Solutions worth $13,549,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Rockefeller Capital Management L.P. lifted its holdings in shares of BioLife Solutions by 81.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider's stock valued at $14,661,000 after buying an additional 262,504 shares during the period. State Street Corp lifted its holdings in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock valued at $35,364,000 after acquiring an additional 95,788 shares during the period. Stephens Investment Management Group LLC boosted its position in BioLife Solutions by 16.7% in the fourth quarter. Stephens Investment Management Group LLC now owns 495,970 shares of the medical equipment provider's stock worth $12,875,000 after purchasing an additional 70,875 shares during the last quarter. Peregrine Capital Management LLC grew its stake in shares of BioLife Solutions by 18.1% during the 4th quarter. Peregrine Capital Management LLC now owns 352,205 shares of the medical equipment provider's stock valued at $9,143,000 after purchasing an additional 54,100 shares during the period. Finally, Principal Financial Group Inc. increased its position in shares of BioLife Solutions by 28.1% during the 4th quarter. Principal Financial Group Inc. now owns 244,247 shares of the medical equipment provider's stock valued at $6,341,000 after purchasing an additional 53,532 shares during the last quarter. Institutional investors own 93.24% of the company's stock.

Remove Ads

Insider Buying and Selling at BioLife Solutions

In other news, EVP Aby J. Mathew sold 7,604 shares of BioLife Solutions stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the sale, the executive vice president now directly owns 276,315 shares of the company's stock, valued at approximately $7,551,688.95. The trade was a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Troy Wichterman sold 987 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the transaction, the chief financial officer now directly owns 121,779 shares of the company's stock, valued at approximately $3,290,468.58. The trade was a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,009 shares of company stock worth $272,594. Insiders own 2.20% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Craig Hallum raised their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Benchmark reiterated a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. TD Cowen upped their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. HC Wainwright lowered their target price on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating on the stock in a research report on Monday, November 18th. Finally, KeyCorp upped their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, BioLife Solutions currently has a consensus rating of "Moderate Buy" and an average target price of $29.43.

BioLife Solutions Price Performance

BLFS stock traded up $0.44 during trading on Tuesday, reaching $24.95. The company's stock had a trading volume of 285,835 shares, compared to its average volume of 260,800. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The company's fifty day moving average is $26.71 and its 200-day moving average is $25.49. The company has a market capitalization of $1.16 billion, a P/E ratio of -23.61 and a beta of 1.91. BioLife Solutions, Inc. has a 1 year low of $14.84 and a 1 year high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million during the quarter, compared to analysts' expectations of $21.73 million. During the same quarter last year, the business posted ($0.21) earnings per share. On average, research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.